[en] Inflammatory bowel disease (IBD), encompassing ulcerative colitis and Crohn's disease, is a group of chronic, immune-mediated disorders of the gastrointestinal tract that present substantial clinical challenges owing to their complex pathophysiology and tendency to relapse. A treat-to-target approach is recommended, involving iterative treatment adjustments to achieve clinical response, reduce inflammatory markers and achieve long-term goals such as mucosal healing. Lifelong medication is often necessary to manage the disease, maintain remission and prevent complications. The therapeutic landscape for IBD has evolved substantially; however, a ceiling on therapeutic efficacy remains and surgery is sometimes required (owing to uncontrolled disease activity or complications). Effective IBD management involves comprehensive care, including medication adherence and a collaborative clinician-patient relationship. This Review discusses current therapeutic options for IBD, detailing mechanisms of action, efficacy, safety profiles and guidelines for use of each drug class. We also explore emerging therapies and the role of surgery. Additionally, the importance of a multidisciplinary team and personalized care in managing IBD is emphasized, advocating for patient empowerment and involvement in treatment decisions. By synthesizing current knowledge and emerging trends, this Review aims to equip healthcare professionals with a thorough understanding of therapeutic options for IBD, enhancing informed, evidence-based decisions in clinical practice.
Disciplines :
Gastroenterology & hepatology
Author, co-author :
Vieujean, Sophie ; Université de Liège - ULiège > Département des sciences cliniques > Hépato-gastroentérologie ; Department of Gastroenterology, INFINY Institute, CHRU Nancy, Vandœuvre-lès-Nancy, France
Jairath, Vipul; Division of Gastroenterology, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada
Peyrin-Biroulet, Laurent ; Department of Gastroenterology, INFINY Institute, CHRU Nancy, Vandœuvre-lès-Nancy, France ; Division of Gastroenterology and Hepatology, McGill University Health Centre, Montreal, Quebec, Canada
Dubinsky, Marla; Department of Paediatrics, Susan and Leonard Feinstein IBD Center, Icahn School of Medicine, Mount Sinai, New York, NY, USA
Iacucci, Marietta; APC Microbiome Ireland, College of Medicine and Health, University College of Cork, Cork, Ireland
Magro, Fernando; CINTESIS@RISE, Faculty of Medicine, University of Porto, Porto, Portugal
Danese, Silvio ; Gastroenterology and Endoscopy, IRCCS Ospedale San Raffaele and University Vita-Salute San Raffaele, Milano, Italy. sdanese@hotmail.com
Language :
English
Title :
Understanding the therapeutic toolkit for inflammatory bowel disease.
J.T. Chang Pathophysiology of Inflammatory Bowel Diseases N. Engl. J. Med. 383 2652 2664 1:CAS:528:DC%2BB3MXotFSntw%3D%3D 33382932 10.1056/NEJMra2002697
D. Turner et al. STRIDE-II: an update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD Gastroenterology 160 1570 1583 1:CAS:528:DC%2BB3MXhsl2qurjN 33359090 10.1053/j.gastro.2020.12.031
C. Le Berre et al. Selecting end points for disease-modification trials in inflammatory bowel disease: the SPIRIT consensus from the IOIBD Gastroenterology 160 1452 1460 33421515 10.1053/j.gastro.2020.10.065
C. Le Berre S. Honap L. Peyrin-Biroulet Ulcerative colitis Lancet 402 571 584 37573077 10.1016/S0140-6736(23)00966-2
M. Dolinger J. Torres S. Vermeire Crohn’s disease Lancet 403 1177 1191 1:CAS:528:DC%2BB2cXltFOltLk%3D 38437854 10.1016/S0140-6736(23)02586-2
T. Raine S. Danese Breaking through the therapeutic ceiling: what will it take? Gastroenterology 162 1507 1511 34995533 10.1053/j.gastro.2021.09.078
D. Alsoud B. Verstockt C. Fiocchi S. Vermeire Breaking the therapeutic ceiling in drug development in ulcerative colitis Lancet Gastroenterol. Hepatol. 6 589 595 34019798 10.1016/S2468-1253(21)00065-0
F. Magro et al. Has the therapeutical ceiling been reached in Crohn’s disease randomized controlled trials? A systematic review and meta-analysis United European Gastroenterol. J. 11 202 217 36876515 10039796 10.1002/ueg2.12366
W.A. Bemelman et al. Evolving role of IBD surgery J. Crohns Colitis 12 1005 1007 1:STN:280:DC%2BC1MjpvVCnsA%3D%3D 29726935 10.1093/ecco-jcc/jjy056
E.J. Villablanca K. Selin C.R.H. Hedin Mechanisms of mucosal healing: treating inflammatory bowel disease without immunosuppression? Nat. Rev. Gastroenterol. Hepatol. 19 493 507 35440774 10.1038/s41575-022-00604-y
N. Svartz Salazopyrin, a new sulfanilamide preparation. A. Therapeutic results in rheumatic polyarthritis. B. Therapeutic effects in ulcerative colitis. C. Toxic manifestations in treatment with sulfanilamide preparations Acta Med. Scand. 110 580 598 10.1111/j.0954-6820.1942.tb06841.x
N. Svartz The treatment of 124 cases of ulcerative colitis with salazopyrine and attempts of desensibilization in cases of hypersensitiveness to sulfa Acta Med. Scand. 130 465 472 10.1111/j.0954-6820.1948.tb12083.x
A.K. Azad Khan J. Piris S.C. Truelove An experiment to determine the active therapeutic moiety of sulphasalazine Lancet 2 892 895 1:STN:280:DyaE1c%2FjtVCktA%3D%3D 72239 10.1016/S0140-6736(77)90831-5
S.C.W.L. Truelove Cortisone in ulcerative colitis final report on a therapeutic trial Br. Med. J. 2 1041 1048 1:STN:280:DyaG28%2Fht1Gksg%3D%3D 13260656 1981500 10.1136/bmj.2.4947.1041
R. BEAN RH The treatment of chronic ulcerative colitis with 6-mercaptopurine Med. J. Aust. 49 592 593 10.5694/j.1326-5377.1962.tb20590.x
R.H.D. Bean Treatment of ulcerative colitis with antimetabolites Br. Med. J. 1 1081 1084 1:STN:280:DC%2BC3MzpslemtQ%3D%3D 20790943 1844002 10.1136/bmj.1.5495.1081
D.P. Jewell S.C. Truelove Azathioprine in ulcerative colitis: final report on controlled therapeutic trial Br. Med. J. 4 627 630 1:STN:280:DyaE2M%2FntlKjsw%3D%3D 4441827 1612983 10.1136/bmj.4.5945.627
D.J. Mulder A.J. Noble C.J. Justinich J.M. Duffin A tale of two diseases: the history of inflammatory bowel disease J. Crohns Colitis 8 341 348 24094598 10.1016/j.crohns.2013.09.009
United States Food and Drug Administration. Product approval for infliximab (FDA, 1998).
S.B. Hanauer et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial Gastroenterology 130 323 333 1:CAS:528:DC%2BD28Xit1alu7o%3D 16472588 10.1053/j.gastro.2005.11.030
W.J. Sandborn et al. Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial Gut 56 1232 1239 1:CAS:528:DC%2BD2sXhtVKgsbnE 17299059 2701613 10.1136/gut.2006.106781
W. Reinisch et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial Gut 60 780 787 1:CAS:528:DC%2BC3MXpt1yktrs%3D 21209123 10.1136/gut.2010.221127
W.J. Sandborn et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis Gastroenterology 142 257 265 1:CAS:528:DC%2BC38XhsVOmu7o%3D 22062358 10.1053/j.gastro.2011.10.032
W. Reinisch et al. 52-week efficacy of adalimumab in patients with moderately to severely active ulcerative colitis who failed corticosteroids and/or immunosuppressants Inflamm. Bowel Dis. 19 1700 1709 23665965 10.1097/MIB.0b013e318281f2b7
W.J. Sandborn et al. Certolizumab pegol for the treatment of Crohn’s disease N. Engl. J. Med. 357 228 238 1:CAS:528:DC%2BD2sXotVaqurY%3D 17634458 10.1056/NEJMoa067594
S. Schreiber et al. Maintenance therapy with certolizumab pegol for Crohn’s disease N. Engl. J. Med. 357 239 250 1:CAS:528:DC%2BD2sXotVejs7g%3D 17634459 10.1056/NEJMoa062897
W.J. Sandborn et al. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis Gastroenterology 146 96 109 1:CAS:528:DC%2BC3sXhvVGqsrzJ 23770005 10.1053/j.gastro.2013.06.010
P. Rutgeerts et al. Randomised clinical trial: a placebo-controlled study of intravenous golimumab induction therapy for ulcerative colitis Aliment. Pharmacol. Ther. 42 504 514 1:CAS:528:DC%2BC2MXht1yqs7bP 26119226 4755132 10.1111/apt.13291
B.G. Feagan et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis N. Engl. J. Med. 369 699 710 1:CAS:528:DC%2BC3sXhtlCrsrbN 23964932 10.1056/NEJMoa1215734
W.J. Sandborn et al. Vedolizumab as induction and maintenance therapy for Crohn’s disease N. Engl. J. Med. 369 711 721 1:CAS:528:DC%2BC3sXhtlCrsrbO 23964933 10.1056/NEJMoa1215739
B.G. Feagan et al. Ustekinumab as Induction and maintenance therapy for Crohn’s disease N. Engl. J. Med. 375 1946 1960 1:CAS:528:DC%2BC28XhvF2ksrfO 27959607 10.1056/NEJMoa1602773
B.E. Sands et al. Ustekinumab as induction and maintenance therapy for ulcerative colitis N. Engl. J. Med. 381 1201 1214 1:CAS:528:DC%2BC1MXhvFWnsbbE 31553833 10.1056/NEJMoa1900750
G. D’Haens et al. Risankizumab as induction therapy for Crohn’s disease: results from the phase 3 ADVANCE and MOTIVATE induction trials Lancet 399 2015 2030 35644154 10.1016/S0140-6736(22)00467-6
M. Ferrante et al. Risankizumab as maintenance therapy for moderately to severely active Crohn’s disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial Lancet 399 2031 2046 1:CAS:528:DC%2BB38XhsVOqsbrN 35644155 10.1016/S0140-6736(22)00466-4
E. Louis et al. Risankizumab for ulcerative colitis: two randomized clinical trials JAMA 332 881 897 1:CAS:528:DC%2BB2cXitVKjs7vE 39037800 11264075 10.1001/jama.2024.12414
G. D’Haens et al. Mirikizumab as induction and maintenance therapy for ulcerative colitis N. Engl. J. Med. 388 2444 2455 37379135 10.1056/NEJMoa2207940
M.A. Peppercorn P. Goldman The role of intestinal bacteria in the metabolism of salicylazosulfapyridine J. Pharmacol. Exp. Ther. 181 555 562 1:CAS:528:DyaE38Xks12qt7c%3D 4402374 10.1016/S0022-3565(25)29238-2
S. Nikfar R. Rahimi A. Rezaie M. Abdollahi A meta-analysis of the efficacy of sulfasalazine in comparison with 5-aminosalicylates in the induction of improvement and maintenance of remission in patients with ulcerative colitis Dig. Dis. Sci. 54 1157 1170 1:CAS:528:DC%2BD1MXlsFKrtb0%3D 18770034 10.1007/s10620-008-0481-x
C. Rousseaux et al. Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-γ J. Exp. Med 201 1205 1215 1:CAS:528:DC%2BD2MXjs1CitLg%3D 15824083 2213148 10.1084/jem.20041948
P. Desreumaux S. Ghosh Review article: mode of action and delivery of 5-aminosalicylic acid — new evidence Aliment. Pharmacol. Ther. 24 2 9 1:CAS:528:DC%2BD28Xht1akt7fN 16939423 10.1111/j.1365-2036.2006.03069.x
J. Słoka M. Madej B. Strzalka-Mrozik Molecular mechanisms of the antitumor effects of mesalazine and its preventive potential in colorectal cancer Molecules 28 5081 37446747 10343926 10.3390/molecules28135081
F.S. Velayos J.P. Terdiman J.M. Walsh Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies Am. J. Gastroenterol. 100 1345 1353 1:CAS:528:DC%2BD2MXmtFarsL4%3D 15929768 10.1111/j.1572-0241.2005.41442.x
L.N. Zhao et al. 5-Aminosalicylates reduce the risk of colorectal neoplasia in patients with ulcerative colitis: an updated meta-analysis PLoS ONE 9 24710620 3978022 10.1371/journal.pone.0094208 e94208
T. Raine et al. ECCO guidelines on therapeutics in ulcerative colitis: medical treatment J. Crohns Colitis 16 2 17 34635919 10.1093/ecco-jcc/jjab178
H. Gordon et al. ECCO guidelines on therapeutics in Crohn’s disease: medical treatment J. Crohns Colitis 18 1531 1555 38877997 10.1093/ecco-jcc/jjae091
S. Campbell S. Ghosh Effective maintenance of inflammatory bowel disease remission by azathioprine does not require concurrent 5-aminosalicylate therapy Eur. J. Gastroenterol. Hepatol. 13 1297 1301 1:CAS:528:DC%2BD38XlvFKgtA%3D%3D 11692054 10.1097/00042737-200111000-00006
G.J. Mantzaris et al. A prospective randomized observer-blind 2-year trial of azathioprine monotherapy versus azathioprine and olsalazine for the maintenance of remission of steroid-dependent ulcerative colitis Am. J. Gastroenterol. 99 1122 1128 1:CAS:528:DC%2BD2cXmt1Chu7o%3D 15180735 10.1111/j.1572-0241.2004.11481.x
S. Singh et al. No benefit of concomitant 5-aminosalicylates in patients with ulcerative colitis escalated to biologic therapy: pooled analysis of individual participant data from clinical trials Am. J. Gastroenterol. 113 1197 1205 1:CAS:528:DC%2BC1cXht1Cgt7jL 29925913 7107271 10.1038/s41395-018-0144-2
G. Doherty et al. European Crohn’s and colitis organisation topical review on treatment withdrawal [’exit strategies’] in inflammatory bowel disease J. Crohns Colitis 12 17 31 28981623 10.1093/ecco-jcc/jjx101
M. Naganuma Solving the questions regarding 5-aminosalitylate formulation in the treatment of ulcerative colitis J. Gastroenterol. 55 1013 1022 1:CAS:528:DC%2BB3cXhsFKlurvE 32778960 7567706 10.1007/s00535-020-01713-8
C.A. Lamb et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults Gut 68 s1 s106 31562236 10.1136/gutjnl-2019-318484
J.D. Feuerstein et al. AGA clinical practice guidelines on the management of moderate to severe ulcerative colitis Gastroenterology 158 1450 1461 31945371 10.1053/j.gastro.2020.01.006
W.J. Sandborn Rational selection of oral 5-aminosalicylate formulations and prodrugs for the treatment of ulcerative colitis Am. J. Gastroenterol. 97 2939 2941 1:CAS:528:DC%2BD3sXhtl2kuw%3D%3D 12492172 10.1111/j.1572-0241.2002.07092.x
A. Murray T.M. Nguyen C.E. Parker B.G. Feagan J.K. MacDonald Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis Cochrane Database Syst. Rev. 8 CD000544 32856298
R.A.J. Ransford M.J.S. Langman Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines Gut 51 536 539 1:CAS:528:DC%2BD3sXhslWmt74%3D 12235076 1773410 10.1136/gut.51.4.536
P. Sehgal J.F. Colombel A. Aboubakr N. Narula Systematic review: safety of mesalazine in ulcerative colitis Aliment. Pharmacol. Ther. 47 1597 1609 1:STN:280:DC%2BC1Mjptl2nug%3D%3D 29722441 10.1111/apt.14688
E.V. Loftus S.V. Kane D. Bjorkman Systematic review: short-term adverse effects of 5-aminosalicylic acid agents in the treatment of ulcerative colitis Aliment. Pharmacol. Ther. 19 179 189 1:CAS:528:DC%2BD2cXhvVCju7Y%3D 14723609 10.1111/j.0269-2813.2004.01827.x
J.G. Moss C.M. Parry R.C.L. Holt S.J. McWilliam 5-ASA induced interstitial nephritis in patients with inflammatory bowel disease: a systematic review Eur. J. Med. Res. 27 61 1:CAS:528:DC%2BB38XhslWqsbfJ 35488310 9052675 10.1186/s40001-022-00687-y
L. Guillo et al. Kidney function monitoring in inflammatory bowel disease: the MONITORED consensus Dig. Liver Dis. 54 309 315 34866011 10.1016/j.dld.2021.11.008
P.M.D. Foster E. Gray H. Leffers N.E. Skakkebæk Disruption of reproductive development in male rat offspring following in utero exposure to phthalate esters Int. J. Androl. 29 140 147 1:CAS:528:DC%2BD28XjslWitrg%3D 16102138 10.1111/j.1365-2605.2005.00563.x
T.S. Kim et al. Effects of in utero exposure to di(n-butyl) phthalate on development of male reproductive tracts in Sprague-Dawley rats J. Toxicol. Environ. Health A 73 1544 1559 1:CAS:528:DC%2BC3cXht12ltL3I 20954080 10.1080/15287394.2010.511579
M.N. Brondfield U. Mahadevan Inflammatory bowel disease in pregnancy and breastfeeding Nat. Rev. Gastroenterol. Hepatol. 20 504 523 37002407 10.1038/s41575-023-00758-3
J.B. Kirsner W.L. Palmer Ulcerative colitis; therapeutic effects of corticotropin (ACTH) and cortisone in 120 patients Ann. Intern. Med 41 232 250 1:STN:280:DyaG2c7gtFCgtA%3D%3D 13181274 10.7326/0003-4819-41-2-232
S. Edsbäcker T. Andersson Pharmacokinetics of budesonide (EntocortTM EC) capsules for Crohn’s disease Clin. Pharmacokinet. 43 803 821 15355126
G.R. Lichtenstein Budesonide multi-matrix for the treatment of patients with ulcerative colitis Dig. Dis. Sci. 61 358 370 1:CAS:528:DC%2BC2MXhvVaqsr3L 26541989 10.1007/s10620-015-3897-0
S. Bruscoli M. Febo C. Riccardi G. Migliorati Glucocorticoid therapy in inflammatory bowel disease: mechanisms and clinical practice Front. Immunol. 12 691480 1:CAS:528:DC%2BB3MXhsFKmtLjN 34149734 8209469 10.3389/fimmu.2021.691480
A.M. Dorrington et al. The historical role and contemporary use of corticosteroids in inflammatory bowel disease J. Crohns Colitis 14 1316 1329 32170314 10.1093/ecco-jcc/jjaa053
Yasir, M. Sonthalia, S. Corticosteroid Adverse Effects. https://www.ncbi.nlm.nih.gov/books/NBK531462/ (StatPearls Publishing, 2018).
P. Sarlos et al. Steroid but not biological therapy elevates the risk of venous thromboembolic events in inflammatory bowel disease: a meta-analysis J. Crohns Colitis 12 489 498 29220427 10.1093/ecco-jcc/jjx162
F.A. Farraye G.Y. Melmed G.R. Lichtenstein S.V. Kane ACG clinical guideline: preventive care in inflammatory bowel disease Am. J. Gastroenterol. 112 241 258 28071656 10.1038/ajg.2016.537
F.D. Odufalu M. Long K. Lin U. Mahadevan Exposure to corticosteroids in pregnancy is associated with adverse perinatal outcomes among infants of mothers with inflammatory bowel disease: results from the PIANO registry Gut 71 1766 1772 34686575 10.1136/gutjnl-2021-325317
M. Löwenberg et al. Mercaptopurine for the treatment of ulcerative colitis: a randomized placebo-controlled trial J. Crohns Colitis 17 1055 1065 36847130 10394500 10.1093/ecco-jcc/jjad022
G. D’Haens et al. Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis Gastroenterology 120 1323 1329 11313301 10.1053/gast.2001.23983
M.M. Estevinho et al. A systematic review and meta-analysis of 6-thioguanine nucleotide levels and clinical remission in inflammatory bowel disease J. Crohn’s Colitis 11 1381 1392 10.1093/ecco-jcc/jjx089
A.M. Alqarni M.P. Zeidler How does methotrexate work? Biochem. Soc. Trans. 48 559 567 1:CAS:528:DC%2BB3cXht1ansr3J 32239204 10.1042/BST20190803
A. Dignass et al. The second European evidence-based consensus on the diagnosis and management of Crohn’s disease: current management J. Crohn’s Colitis 4 28 62 1:STN:280:DC%2BC3M%2Fjs1OmsA%3D%3D 10.1016/j.crohns.2009.12.002
N. Chande C.M. Townsend C.E. Parker J.K. Macdonald Azathioprine or 6-mercaptopurine for induction of remission in Crohn’s disease Cochrane Database Syst. Rev. 10 CD000545 27783843
S. Singh et al. AGA living clinical practice guideline on pharmacological management of moderate-to-severe ulcerative colitis Gastroenterology 167 1307 1343 1:CAS:528:DC%2BB2cXisFOltrrE 39572132 10.1053/j.gastro.2024.10.001
J.D. Feuerstein et al. AGA clinical practice guidelines on the medical management of moderate to severe luminal and perianal fistulizing Crohn’s disease Gastroenterology 160 2496 2508 34051983 10.1053/j.gastro.2021.04.022
B.G. Feagan et al. Methotrexate for the treatment of Crohn’s disease N. Engl. J. Med. 332 292 297 1:STN:280:DyaK2M7hsFOitA%3D%3D 7816064 10.1056/NEJM199502023320503
B.G. Feagan et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn’s disease N. Engl. J. Med. 342 1627 1632 1:CAS:528:DC%2BD3cXktF2gsr4%3D 10833208 10.1056/NEJM200006013422202
T. Raine et al. ECCO topical review: refractory inflammatory bowel disease J. Crohns Colitis 15 1605 1620 34160593 10.1093/ecco-jcc/jjab112
N.A. Kennedy et al. Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn’s disease: a prospective, multicentre, cohort study Lancet Gastroenterol. Hepatol. 4 341 353 30824404 10.1016/S2468-1253(19)30012-3
J.F. Colombel et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease N. Engl. J. Med. 362 1383 1395 1:CAS:528:DC%2BC3cXkslajt78%3D 20393175 10.1056/NEJMoa0904492
S. Lichtiger et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy N. Engl. J. Med. 330 1841 1845 1:STN:280:DyaK2c3lsV2ltA%3D%3D 8196726 10.1056/NEJM199406303302601
M.B. Sternthal et al. Adverse events associated with the use of cyclosporine in patients with inflammatory bowel disease Am. J. Gastroenterol. 103 937 943 1:CAS:528:DC%2BD1cXls1Cqsb8%3D 18177449 10.1111/j.1572-0241.2007.01718.x
R.L. Roberts M.L. Barclay Update on thiopurine pharmacogenetics in inflammatory bowel disease Pharmacogenomics 16 891 903 1:CAS:528:DC%2BC2MXhtFCksbnK 26067482 10.2217/pgs.15.29
G.J. Walker et al. Association of genetic variants in NUDT15 with thiopurine-induced myelosuppression in patients with inflammatory bowel disease JAMA 321 753 761 10.1001/jama.2019.0709
R. de Francisco et al. Impact of Epstein–Barr virus serological status on clinical outcomes in adult patients with inflammatory bowel disease Aliment. Pharmacol. Ther. 48 723 730 30095176 10.1111/apt.14933
P.S. Dulai C.A. Siegel J.F. Colombel W.J. Sandborn L. Peyrin-Biroulet Systematic review: monotherapy with antitumour necrosis factor α agents versus combination therapy with an immunosuppressive for IBD Gut 63 1843 1853 1:CAS:528:DC%2BC2MXhs1aqtw%3D%3D 24970900 10.1136/gutjnl-2014-307126
S.Z. Huang et al. Risk of skin cancers in thiopurines-treated and thiopurines-untreated patients with inflammatory bowel disease: a systematic review and meta-analysis J. Gastroenterol. Hepatol. 34 507 516 30393891 10.1111/jgh.14533
H. Gordon et al. ECCO guidelines on inflammatory bowel disease and malignancies J. Crohns Colitis 17 827 854 36528797 10.1093/ecco-jcc/jjac187
M.D. Long et al. Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease Clin. Gastroenterol. Hepatol. 8 268 274 20005977 2838486 10.1016/j.cgh.2009.11.024
W. Sandborn W. Tremaine Cyclosporine treatment of inflammatory bowel disease Mayo Clin. Proc. 67 981 990 1:STN:280:DyaK3s%2FmtFeiug%3D%3D 1434859 10.1016/S0025-6196(12)60930-6
J. Torres et al. European Crohn’s and colitis guidelines on sexuality, fertility, pregnancy, and lactation J. Crohns Colitis 17 1 27 36005814 10.1093/ecco-jcc/jjac115
J.A. Martínez Lopez E. Loza L. Carmona Systematic review on the safety of methotrexate in rheumatoid arthritis regarding the reproductive system (fertility, pregnancy, and breastfeeding) Clin. Exp. Rheumatol. 27 678 684 19772806
C. Weber-Schoendorfer et al. Pregnancy outcome after methotrexate treatment for rheumatic disease prior to or during early pregnancy: a prospective multicenter cohort study Arthritis Rheumatol. 66 1101 1110 1:CAS:528:DC%2BC2cXhtlyktLbI 24470106 10.1002/art.38368
S. Rutella et al. Infliximab therapy inhibits inflammation-induced angiogenesis in the mucosa of patients with Crohn’s disease Am. J. Gastroenterol. 106 762 770 1:CAS:528:DC%2BC3MXkt1eiu7Y%3D 21364546 10.1038/ajg.2011.48
R. Atreya et al. Antibodies against tumor necrosis factor (TNF) induce T-cell apoptosis in patients with inflammatory bowel diseases via TNF receptor 2 and intestinal CD14+ macrophages Gastroenterology 141 2026 2038 1:CAS:528:DC%2BC3MXhsFSjt7zK 21875498 10.1053/j.gastro.2011.08.032
J.M.H. Van Den Brande et al. Prediction of antitumour necrosis factor clinical efficacy by real-time visualisation of apoptosis in patients with Crohn’s disease Gut 56 509 517 17082252 10.1136/gut.2006.105379
C. Günther et al. Caspase-8 regulates TNF-α-induced epithelial necroptosis and terminal ileitis Nature 477 335 339 21921917 3373730 10.1038/nature10400
K. Juuti-Uusitalo et al. Differential effects of TNF (TNFSF2) and IFN-γ on intestinal epithelial cell morphogenesis and barrier function in three-dimensional culture PLoS ONE 6 1:CAS:528:DC%2BC3MXhtFCkur7O 21853060 3154921 10.1371/journal.pone.0022967 e22967
M.J. Meijer et al. Effect of the anti-tumor necrosis factor-α antibody infliximab on the ex vivo mucosal matrix metalloproteinase-proteolytic phenotype in inflammatory bowel disease Inflamm. Bowel Dis. 13 200 210 17206679 10.1002/ibd.20051
M.F. Neurath Current and emerging therapeutic targets for IBD Nat. Rev. Gastroenterol. Hepatol. 14 269 278 1:CAS:528:DC%2BC2sXhvV2ht7w%3D 28144028 10.1038/nrgastro.2016.208
M. Berns D.W. Hommes Anti-TNF-α therapies for the treatment of Crohn’s disease: the past, present and future Expert Opin. Investig. Drugs 25 129 143 1:CAS:528:DC%2BC28Xlt1Gguw%3D%3D 26616476 10.1517/13543784.2016.1126247
T. Ten Hove M.C. Van M.P. Peppelenbosch S.J.H. Van Deventer Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn’s disease Gut 50 206 211 11788561 1773100 10.1136/gut.50.2.206
S.B. Hanauer et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial Lancet 359 1541 1549 1:CAS:528:DC%2BD38Xkt1Gru70%3D 12047962 10.1016/S0140-6736(02)08512-4
B.E. Sands et al. Infliximab maintenance therapy for fistulizing Crohn’s disease N. Engl. J. Med. 350 876 885 1:CAS:528:DC%2BD2cXhsFyitLo%3D 14985485 10.1056/NEJMoa030815
P. Rutgeerts et al. Infliximab for induction and maintenance therapy for ulcerative colitis N. Engl. J. Med. 353 2462 2476 1:CAS:528:DC%2BD2MXhtlShurjE 16339095 10.1056/NEJMoa050516
J.F. Colombel et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial Gastroenterology 132 52 65 1:CAS:528:DC%2BD2sXit1aqsLw%3D 17241859 10.1053/j.gastro.2006.11.041
J.F. Colombel et al. Adalimumab for the treatment of fistulas in patients with Crohn’s disease Gut 58 940 948 1:CAS:528:DC%2BD1MXovFSktbw%3D 19201775 10.1136/gut.2008.159251
K. Papamichael et al. Review article: pharmacological aspects of anti-TNF biosimilars in inflammatory bowel diseases Aliment. Pharmacol. Ther. 42 1158 1169 1:CAS:528:DC%2BC2MXhs1Ohu73I 26365281 10.1111/apt.13402
K.K. Jørgensen et al. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial Lancet 389 2304 2316 28502609 10.1016/S0140-6736(17)30068-5
United States Food and Drug Administration. Scientific considerations in demonstrating biosimilarity to a reference product (FDA, 2015).
W. Park et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study Ann. Rheum. Dis. 72 1605 1612 1:CAS:528:DC%2BC3sXhs1eis7nM 23687259 10.1136/annrheumdis-2012-203091
D.H. Yoo et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study Ann. Rheum. Dis. 72 1613 1620 1:CAS:528:DC%2BC3sXhs1eis7nN 23687260 10.1136/annrheumdis-2012-203090
K. Papamichael A.S. Cheifetz Therapeutic drug monitoring in patients on biologics: lessons from Gastroenterology Curr. Opin. Rheumatol. 32 371 379 1:CAS:528:DC%2BB3cXhtVWjurvP 32412995 8294174 10.1097/BOR.0000000000000713
S. Marquez-Megias et al. Cost-effectiveness of therapeutic drug monitoring of anti-TNF therapy in inflammatory bowel disease: a systematic review Pharmaceutics 14 1009 1:CAS:528:DC%2BB38XhsV2jtLfN 35631594 9145467 10.3390/pharmaceutics14051009
P.M. Irving K.B. Gecse Optimizing therapies using therapeutic drug monitoring: current strategies and future perspectives Gastroenterology 162 1512 1524 1:CAS:528:DC%2BB38XhtlanurvI 35167865 10.1053/j.gastro.2022.02.014
A.S. Cheifetz et al. A comprehensive literature review and expert consensus statement on therapeutic drug monitoring of biologics in inflammatory bowel disease Am. J. Gastroenterol. 116 2014 2025 1:CAS:528:DC%2BB3sXntl2rsLY%3D 34388143 9674375 10.14309/ajg.0000000000001396
R.W. Stidham et al. Systematic review with network meta-analysis: the efficacy of anti-TNF agents for the treatment of Crohn’s disease Aliment. Pharmacol. Ther. 39 1349 1362 1:CAS:528:DC%2BC2cXos1WlurY%3D 24749763 7006346 10.1111/apt.12749
O.H. Nielsen M.A. Ainsworth Tumor necrosis factor inhibitors for inflammatory bowel disease N. Engl. J. Med. 369 754 762 1:CAS:528:DC%2BC3sXhtlCrsrbK 23964937 10.1056/NEJMct1209614
J.P. Gisbert J. Panés Loss of response and requirement of infliximab dose intensification in Crohn’s disease: a review Am. J. Gastroenterol. 104 760 767 1:CAS:528:DC%2BD1MXis1artbo%3D 19174781
J.D. Feuerstein et al. American gastroenterological association institute guideline on therapeutic drug monitoring in inflammatory bowel disease Gastroenterology 153 827 834 28780013 10.1053/j.gastro.2017.07.032
F. Baert et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s disease N. Engl. J. Med. 348 601 608 1:CAS:528:DC%2BD3sXhtVyqtL0%3D 12584368 10.1056/NEJMoa020888
C. Steenholdt et al. Changes in serum trough levels of infliximab during treatment intensification but not in antiinfliximab antibody detection are associated with clinical outcomes after therapeutic failure in Crohn’s disease J. Crohns Colitis 9 238 245 25576753 10.1093/ecco-jcc/jjv004
E. Dreesen et al. Anti-infliximab antibody concentrations can guide treatment intensification in patients with Crohn’s disease who lose clinical response Aliment. Pharmacol. Ther. 47 346 355 1:CAS:528:DC%2BC1cXmt1eltw%3D%3D 29226370 10.1111/apt.14452
R. Panaccione et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis Gastroenterology 146 392 400 1:CAS:528:DC%2BC2cXhsVOlt78%3D 24512909 10.1053/j.gastro.2013.10.052
I. Ordás B.G. Feagan W.J. Sandborn Early use of immunosuppressives or TNF antagonists for the treatment of Crohn’s disease: time for a change Gut 60 1754 1763 21997558 10.1136/gutjnl-2011-300934
N.M. Noor et al. A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn’s disease (PROFILE): a multicentre, open-label randomised controlled trial Lancet Gastroenterol. Hepatol. 9 415 427 1:CAS:528:DC%2BB2cXit1Skt7zN 38402895 11001594 10.1016/S2468-1253(24)00034-7
R. Khanna et al. Early combined immunosuppression for the management of Crohn’s disease (REACT): a cluster randomised controlled trial Lancet 386 1825 1834 26342731 10.1016/S0140-6736(15)00068-9
G. D’Haens et al. Subcutaneous infliximab monotherapy versus combination therapy with immunosuppressants in inflammatory bowel disease: a post hoc analysis of a randomised clinical trial Clin. Drug Investig. 43 277 288 37004656 10066948 10.1007/s40261-023-01252-z
J. Kirchgesner et al. Risk of serious and opportunistic infections associated with treatment of inflammatory bowel diseases Gastroenterology 155 337 346 29655835 10.1053/j.gastro.2018.04.012
C.M. Townsend F. Lovegrove R. Khanna A.S. Wilson Review article: paradoxical psoriasis as a consequence of tumour necrosis factor antagonists in patients with inflammatory bowel disease Aliment. Pharmacol. Ther. 55 1379 1388 35312094 10.1111/apt.16883
I.B. McInnes et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial Lancet 382 780 789 1:CAS:528:DC%2BC3sXpsV2ksbw%3D 23769296 10.1016/S0140-6736(13)60594-2
M. Muller F. D’Amico S. Bonovas S. Danese L. Peyrin-Biroulet TNF inhibitors and risk of malignancy in patients with inflammatory bowel diseases: a systematic review J. Crohns Colitis 15 840 859 32915970 10.1093/ecco-jcc/jjaa186
A. Chupin et al. Systematic review with meta-analysis: comparative risk of lymphoma with anti-tumour necrosis factor agents and/or thiopurines in patients with inflammatory bowel disease Aliment. Pharmacol. Ther. 52 1289 1297 1:CAS:528:DC%2BB3cXhvFajsrfO 32840893 10.1111/apt.16050
M. Briskin et al. Human mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue Am. J. Pathol. 151 97 110 1:CAS:528:DyaK2sXkslart7c%3D 9212736 1857942
D. Picarella et al. Monoclonal antibodies specific for β7 integrin and mucosal addressin cell adhesion molecule-1 (MAdCAM-1) reduce inflammation in the colon of scid mice reconstituted with CD45RBhigh CD4+ T cells J. Immunol. 158 2099 2106 1:CAS:528:DyaK2sXhtlGms7s%3D 9036954 10.4049/jimmunol.158.5.2099
C.H. Polman et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis N. Engl. J. Med. 354 899 910 1:CAS:528:DC%2BD28XitVertL4%3D 16510744 10.1056/NEJMoa044397
T.A. Yednock et al. Prevention of experimental autoimmune encephalomyelitis by antibodies against α4β1 integrin Nature 356 63 66 1:CAS:528:DyaK38Xhslaisbw%3D 1538783 10.1038/356063a0
S.R. Targan et al. Natalizumab for the treatment of active Crohn’s disease: results of the ENCORE trial Gastroenterology 132 1672 1683 1:CAS:528:DC%2BD2sXmsVymsrc%3D 17484865 10.1053/j.gastro.2007.03.024
T.A. Yousry et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy N. Engl. J. Med. 354 924 933 1:CAS:528:DC%2BD28XitVertLs%3D 16510746 1934511 10.1056/NEJMoa054693
United States Department of Health &; Human Services. Drug details — natalizumab (FDA, 2015).
G. D’Haens et al. Vedolizumab to prevent postoperative recurrence of Crohn’s disease (REPREVIO): a multicentre, double-blind, randomised, placebo-controlled trial Lancet Gastroenterol. Hepatol. 10 26 33 39571587 10.1016/S2468-1253(24)00317-0
B.E. Sands et al. Effects of vedolizumab induction therapy for patients with Crohn’s disease in whom tumor necrosis factor antagonist treatment failed Gastroenterology 147 618 627 1:CAS:528:DC%2BC2cXhsV2ltbnN 24859203 10.1053/j.gastro.2014.05.008
B.G. Feagan et al. Efficacy of vedolizumab induction and maintenance therapy in patients with ulcerative colitis, regardless of prior exposure to tumor necrosis factor antagonists Clin. Gastroenterol. Hepatol. 15 229 239 1:CAS:528:DC%2BC28XhslKnu7fP 27639327 10.1016/j.cgh.2016.08.044
C. Yzet et al. No benefit of concomitant immunomodulator therapy on efficacy of biologics that are not tumor necrosis factor antagonists in patients with inflammatory bowel diseases: a meta-analysis Clin. Gastroenterol. Hepatol. 19 668 679 1:CAS:528:DC%2BB3cXhsFyitbbM 32629124 10.1016/j.cgh.2020.06.071
S. Travis et al. Vedolizumab for the treatment of chronic pouchitis N. Engl. J. Med. 388 1191 1200 1:CAS:528:DC%2BB3sXnsVags7k%3D 36988594 10.1056/NEJMoa2208450
G. Van Assche et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 3: special situations J. Crohns Colitis 7 1 33 23040453 10.1016/j.crohns.2012.09.005
S. Rohekar et al. Initiation of vedolizumab did not provoke new-onset spondylarthritis in patients with inflammatory bowel disease: a prospective 24-week study with imaging assessments United European Gastroenterol. J. 12 859 869 1:CAS:528:DC%2BB2cXhsFektb7N 38965810 11497674 10.1002/ueg2.12621
H.H. Uhlig et al. Differential activity of IL-12 and IL-23 in mucosal and systemic innate immune pathology Immunity 25 309 318 1:CAS:528:DC%2BD28XpvVGjsrk%3D 16919486 10.1016/j.immuni.2006.05.017
C.L. Langrish et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation J. Exp. Med 201 233 240 1:CAS:528:DC%2BD2MXot12mtA%3D%3D 15657292 2212798 10.1084/jem.20041257
W.T. Watford B.D. Hissong J.H. Bream Y. Kanno L. Muul O’Shea JJ. Signaling by IL-12 and IL-23 and the immunoregulatory roles of STAT4 Immunol. Rev. 202 139 156 1:CAS:528:DC%2BD2MXhs1Ohsw%3D%3D 15546391 10.1111/j.0105-2896.2004.00211.x
G. Trinchieri Interleukin-12 and the regulation of innate resistance and adaptive immunity Nat. Rev. Immunol. 3 133 146 1:CAS:528:DC%2BD3sXot12gug%3D%3D 12563297 10.1038/nri1001
E. Bettelli et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells Nature 441 235 238 1:CAS:528:DC%2BD28XksVGns7g%3D 16648838 10.1038/nature04753
I.I. Ivanov et al. The orphan nuclear receptor RORγt directs the differentiation program of proinflammatory IL-17+ T helper cells Cell 126 1121 1133 1:CAS:528:DC%2BD28XhtVCnsrrE 16990136 10.1016/j.cell.2006.07.035
M.W.L. Teng et al. IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases Nat. Med 21 719 729 1:CAS:528:DC%2BC2MXhtFeisrvL 26121196 10.1038/nm.3895
L. Niederreiter T. Adolph A. Kaser Anti-IL-12/23 in Crohn’s disease: bench and bedside Curr. Drug Targets 14 1379 1384 1:CAS:528:DC%2BC3sXhslyqu7%2FL 24138637 10.2174/13894501113146660229
No authors listed. The efficacy and safety of guselkumab induction therapy in patients with moderately to severely active ulcerative colitis: results from the phase 3 QUASAR induction study. Gastroenterol. Hepatol.19, 9–10 (2023).
D.T. Rubin et al. The efficacy and safety of guselkumab as maintenance therapy in patients with moderately to severely active ulcerative colitis: results from the phase 3 QUASAR maintenance study Gastroenterology 166 S-180 10.1016/S0016-5085(24)00910-7
Johnson & Johnson Media Center. Tremfya (guselkumab) demonstrates impressive results across biologic-naive and biologic-refractory patients in Crohn’s disease and ulcerative colitis. Johnson & Johnson (10 October 2024).
D. Choi B. McDonald D.T. Rubin Immediate infusion reaction to intravenous risankizumab-rzaa but subsequent tolerance to subcutaneous risankizumab-rzaa ACG Case Rep. J. 11 39507504 11540427 10.14309/crj.0000000000001546 e01546
A.M. Johnson et al. The real-world effectiveness and safety of ustekinumab in the treatment of Crohn’s disease: results from the SUCCESS consortium Am. J. Gastroenterol. 118 317 328 1:CAS:528:DC%2BB3sXhtFChu7rE 36191274 10.14309/ajg.0000000000002047
B.G. Feagan et al. Risankizumab in patients with moderate to severe Crohn’s disease: an open-label extension study Lancet Gastroenterol. Hepatol. 3 671 680 30056030 10.1016/S2468-1253(18)30233-4
United States Food and Drug Administration. Omvoh (mirikizumab-mrkz) label (FDA, 2023).
United States Food and Drug Administration. Skyrizi (risankizumab) label (FDA, 2022).
R. Chugh et al. Maternal and neonatal outcomes in vedolizumab- and ustekinumab-exposed pregnancies: results from the PIANO registry Am. J. Gastroenterol. 119 468 476 1:CAS:528:DC%2BB2cXht1OjsL3I 37796648 10.14309/ajg.0000000000002553
J.E. Darnell M. Kerr lan G.R. Stark Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins Science 264 1415 1421 1:CAS:528:DyaK2cXktlalsL4%3D 8197455 10.1126/science.8197455
A. Salas et al. JAK–STAT pathway targeting for the treatment of inflammatory bowel disease Nat. Rev. Gastroenterol. Hepatol. 17 323 337 32203403 10.1038/s41575-020-0273-0
W.J. Sandborn et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis N. Engl. J. Med. 376 1723 1736 1:CAS:528:DC%2BC2sXhtlOns7jP 28467869 10.1056/NEJMoa1606910
J.F. Colombel et al. Maintenance of remission with tofacitinib therapy in patients with ulcerative colitis Clin. Gastroenterol. Hepatol. 20 116 125 1:CAS:528:DC%2BB3cXislSht7nJ 33039585 10.1016/j.cgh.2020.10.004
B.G. Feagan et al. Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial Lancet 397 2372 2384 1:CAS:528:DC%2BB3MXhsVegurfE 34090625 10.1016/S0140-6736(21)00666-8
S. Danese et al. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials Lancet 399 2113 2128 1:CAS:528:DC%2BB38XhsVOqsbzL 35644166 10.1016/S0140-6736(22)00581-5
J. Panés et al. Tofacitinib for induction and maintenance therapy of Crohn’s disease: results of two phase IIb randomised placebo-controlled trials Gut 66 1049 1059 28209624 10.1136/gutjnl-2016-312735
E.V. Loftus et al. Upadacitinib induction and maintenance therapy for Crohn’s disease N. Engl. J. Med. 388 1966 1980 1:CAS:528:DC%2BB3sXhtFeltLvN 37224198 10.1056/NEJMoa2212728
N. Khan et al. Efficacy of recombinant zoster vaccine in patients with inflammatory bowel disease Clin. Gastroenterol. Hepatol. 20 1570 1578 1:CAS:528:DC%2BB3MXitlCntrvO 34274513 10.1016/j.cgh.2021.07.023
G.S. Kochhar et al. Effectiveness of recombinant zoster vaccine (RZV) in patients with inflammatory bowel disease Vaccine 39 4199 4202 1:CAS:528:DC%2BB3MXhvFGjsbjO 34140170 10.1016/j.vaccine.2021.05.043
T.C. Anderson et al. Use of recombinant zoster vaccine in immunocompromised adults aged ≥19 years: recommendations of the Advisory Committee on Immunization Practices — United States, 2022 MMWR Morb. Mortal Wkly Rep. 71 80 84 1:CAS:528:DC%2BB38XjtFGjsbk%3D 35051134 8774159 10.15585/mmwr.mm7103a2
L. Hoisnard et al. Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database Sci. Rep. 12 7140 1:CAS:528:DC%2BB38Xht1ShsbrO 35504889 9065106 10.1038/s41598-022-10777-w
W.J. Sandborn et al. Tofacitinib for the treatment of ulcerative colitis: an integrated summary of up to 7.8 years of safety data from the global clinical programme J. Crohns Colitis 17 338 351 36124702 10.1093/ecco-jcc/jjac141
M. Ayoub S. Mattay A.J. Yarur P. Deepak Managing risks with newer oral small molecules in patients with inflammatory bowel diseases Curr. Gastroenterol. Rep. 26 145 156 38353899 10.1007/s11894-024-00923-x
United States Food and Drug Administration. FDA approves Boxed Warning about increased risk of blood clots and death with higher dose of arthritis and ulcerative colitis medicine tofacitinib (Xeljanz, Xeljanz XR). https://www.fda.gov/drugs/fda-drug-safety-podcasts/fda-approves-boxed-warning-about-increased-risk-blood-clots-and-death-higher-dose-arthritis-and (2019).
S.R. Ytterberg et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis N. Engl. J. Med. 386 316 326 1:CAS:528:DC%2BB38XisFSlu7c%3D 35081280 10.1056/NEJMoa2109927
J.R. Curtis et al. Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial Ann. Rheum. Dis. 82 331 343 1:CAS:528:DC%2BB3sXmsVOqu7Y%3D 36600185 10.1136/ard-2022-222543
W.J. Sandborn et al. Safety and efficacy of tofacitinib for treatment of ulcerative colitis: final analysis of OCTAVE Open, an open-label, long-term extension study with up to 7.0 years of treatment Aliment. Pharmacol. Ther. 55 464 478 1:CAS:528:DC%2BB38XltV2ltbY%3D 34854095 10.1111/apt.16712
C. Charles-Schoeman et al. Risk factors for major adverse cardiovascular events in phase III and long-term extension studies of tofacitinib in patients with rheumatoid arthritis Arthritis Rheumatol. 71 1450 1459 1:CAS:528:DC%2BC1MXhs1ymtLzK 31385441 6754249 10.1002/art.40911
B. Fernández-Gutiérrez et al. Cardiovascular disease in immune-mediated inflammatory diseases: a cross-sectional analysis of 6 cohorts Medicine 96 28658137 5500059 10.1097/MD.0000000000007308 e7308
M. Argollo et al. Comorbidities in inflammatory bowel disease: a call for action Lancet Gastroenterol. Hepatol. 4 643 654 31171484 10.1016/S2468-1253(19)30173-6
C. Bezzio et al. Cancer risk in patients treated with the JAK inhibitor tofacitinib: systematic review and meta-analysis Cancers 15 2197 1:CAS:528:DC%2BB3sXpsF2hs78%3D 37190126 10136459 10.3390/cancers15082197
S. Harnik B. Ungar R. Loebstein S. Ben-Horin A Gastroenterologist’s guide to drug interactions of small molecules for inflammatory bowel disease United European Gastroenterol. J. 12 627 637 38532266 11176903 10.1002/ueg2.12559
J. Chun G. Giovannoni S.F. Hunter Sphingosine 1-phosphate receptor modulator therapy for multiple sclerosis: differential downstream receptor signalling and clinical profile effects Drugs 81 207 231 1:CAS:528:DC%2BB3cXis1ShtrrL 33289881 10.1007/s40265-020-01431-8
T. Pérez-Jeldres et al. Cell trafficking interference in inflammatory bowel disease: therapeutic interventions based on basic pathogenesis concepts Inflamm. Bowel Dis. 25 270 282 30165490 10.1093/ibd/izy269
V. Brinkmann Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology Pharmacol. Ther. 115 84 105 1:CAS:528:DC%2BD2sXntFyiur0%3D 17561264 10.1016/j.pharmthera.2007.04.006
L. Peyrin-Biroulet R. Christopher D. Behan C. Lassen Modulation of sphingosine-1-phosphate in inflammatory bowel disease Autoimmun. Rev. 16 495 503 1:CAS:528:DC%2BC2sXkslOms7o%3D 28279838 10.1016/j.autrev.2017.03.007
N. Becher A. Swaminath K. Sultan A literature review of ozanimod therapy in inflammatory bowel disease: from concept to practical application Ther. Clin. Risk Manag 18 913 927 36106049 9467694 10.2147/TCRM.S336139
D. Marsolais H. Rosen Chemical modulators of sphingosine-1-phosphate receptors as barrier-oriented therapeutic molecules Nat. Rev. Drug Discov. 8 297 307 1:CAS:528:DC%2BD1MXjtlyms70%3D 19300460 4455967 10.1038/nrd2356
T. Pérez-Jeldres M. Alvarez-Lobos J. Rivera-Nieves Targeting sphingosine-1-phosphate signaling in immune-mediated diseases: beyond multiple sclerosis Drugs 81 985 1002 33983615 8116828 10.1007/s40265-021-01528-8
R.L. Proia T. Hla Emerging biology of sphingosine-1-phosphate: its role in pathogenesis and therapy J. Clin. Invest 125 1379 1387 25831442 4409021 10.1172/JCI76369
W.J. Sandborn et al. Ozanimod as induction and maintenance therapy for ulcerative colitis N. Engl. J. Med. 385 1280 1291 1:CAS:528:DC%2BB3MXitFGnt7rM 34587385 10.1056/NEJMoa2033617
F.L. Scott et al. Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1) and receptor-5 (S1P5) agonist with autoimmune disease-modifying activity Br. J. Pharm. 173 1778 1792 1:CAS:528:DC%2BC28XmvVOnu7g%3D 10.1111/bph.13476
W.J. Sandborn et al. Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies Lancet 401 1159 1171 36871574 10.1016/S0140-6736(23)00061-2
S. Danese et al. Efficacy and safety of approximately 3 years of continuous ozanimod in moderately to severely active ulcerative colitis: interim analysis of the true north open-label extension J. Crohns Colitis 18 264 274 37651686 10.1093/ecco-jcc/jjad146
M. Regueiro et al. Etrasimod for the treatment of ulcerative colitis: analysis of infection events from the ELEVATE UC clinical programme J. Crohns Colitis 18 1596 1605 38700040 11479712 10.1093/ecco-jcc/jjae060
B.E. Sands et al. Clinician’s guide to using ozanimod for the treatment of ulcerative colitis J. Crohns Colitis 17 2012 2025 37436357 10798866 10.1093/ecco-jcc/jjad112
United States Food and Drug Administration. Medication guide: ZEPOSIA (ozanimod) capsules for oral use. FDA https://www.fda.gov/drugs/development-approval-process-drugs/drug-trials-snapshots-zeposia (2024).
M.C. Dubinsky et al. DOP53 pregnancy outcomes in the ozanimod clinical development program in relapsing multiple sclerosis, ulcerative colitis, and Crohn’s disease J. Crohns Colitis 15 S088 S089 10.1093/ecco-jcc/jjab073.092
J.F. Colombel et al. Effect of tight control management on Crohn’s disease (CALM): a multicentre, randomised, controlled phase 3 trial Lancet 390 2779 2789 29096949 10.1016/S0140-6736(17)32641-7
E. Louis et al. Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn’s disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trial Lancet Gastroenterol. Hepatol. 8 215 227 1:CAS:528:DC%2BB2cXitlKnur3K 36640794 9908559 10.1016/S2468-1253(22)00385-5
B.E. Sands et al. Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis N. Engl. J. Med. 381 1215 1226 1:CAS:528:DC%2BC1MXhvFWnsbbO 31553834 10.1056/NEJMoa1905725
B.E. Sands et al. Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn’s disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial Lancet 399 2200 2211 1:CAS:528:DC%2BB38Xit1Wjt77O 35691323 10.1016/S0140-6736(22)00688-2
L. Peyrin-Biroulet et al. Risankizumab versus ustekinumab for moderate-to-severe Crohn’s disease N. Engl. J. Med. 391 213 223 1:CAS:528:DC%2BB2cXhvVaiur3N 39018531 10.1056/NEJMoa2314585
M. Ferrante et al. Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn’s disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study Lancet 404 2423 2436 1:CAS:528:DC%2BB2cXislSiurrN 39581202 10.1016/S0140-6736(24)01762-8
US National Library of Medicine. ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT06052059 (2025).
US National Library of Medicine. ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT06430801 (2025).
B.E. Sands et al. Efficacy and safety of combination induction therapy with guselkumab and golimumab in participants with moderately to severely active ulcerative colitis: results through week 12 of a phase 2a randomized, double-blind, active-controlled, parallel-group, multicenter, proof-of-concept study Gastroenterol. Hepatol. 18 9
S.V. Patel et al. Laparoscopic surgery for Crohn’s disease: a meta-analysis of perioperative complications and long term outcomes compared with open surgery BMC Surg. 13 14 23705825 3733939 10.1186/1471-2482-13-14
M. Adamina et al. ECCO guidelines on therapeutics in Crohn’s disease: surgical treatment J. Crohns Colitis. 18 1556 1582 38878002 10.1093/ecco-jcc/jjae089
C.Y. Ponsioen et al. Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn’s disease: a randomised controlled, open-label, multicentre trial Lancet Gastroenterol. Hepatol. 2 785 792 28838644 10.1016/S2468-1253(17)30248-0
T.W. Stevens et al. Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn’s disease: retrospective long-term follow-up of the LIR!C trial Lancet Gastroenterol. Hepatol. 5 900 907 32619413 10.1016/S2468-1253(20)30117-5
É.J. Ryan et al. Meta-analysis of early bowel resection versus initial medical therapy in patient’s with ileocolonic Crohn’s disease Int. J. Colorectal Dis. 35 501 512 31915984 10.1007/s00384-019-03479-9
S. Singh et al. Postoperative mortality among patients with inflammatory bowel diseases: a systematic review and meta-analysis of population-based studies Gastroenterology 149 928 937 26055136 10.1053/j.gastro.2015.06.001
D. Bettenworth et al. A pooled analysis of efficacy, safety, and long-term outcome of endoscopic balloon dilation therapy for patients with stricturing Crohn’s disease Inflamm. Bowel Dis. 23 133 142 28002130 10.1097/MIB.0000000000000988
E.A. Maser et al. High rates of metachronous colon cancer or dysplasia after segmental resection or subtotal colectomy in Crohn’s colitis Inflamm. Bowel Dis. 19 1827 1832 23669402
O. Olén et al. Colorectal cancer in Crohn’s disease: a Scandinavian population-based cohort study Lancet Gastroenterol. Hepatol. 5 475 484 32066530 10.1016/S2468-1253(20)30005-4
S.H. Feroz A. Ahmed A. Muralidharan P. Thirunavukarasu Comparison of the efficacy of the various treatment modalities in the management of perianal Crohn’s fistula: a review Cureus 12 33415035 7781784 e11882
M. Gordon et al. Infliximab for medical induction of remission in Crohn’s disease Cochrane Database Syst. Rev. 11 CD012623 37982428
K.J. Khan et al. Antibiotic therapy in inflammatory bowel disease: A systematic review and meta-analysis Am. J. Gastroenterol. 106 661 673 1:CAS:528:DC%2BC3MXkt1eiurg%3D 21407187 10.1038/ajg.2011.72
P. Dewint et al. Adalimumab combined with ciprofloxacin is superior to adalimumab monotherapy in perianal fistula closure in Crohn’s disease: a randomised, double-blind, placebo controlled trial (ADAFI) Gut 63 292 299 1:CAS:528:DC%2BC2cXkslartrk%3D 23525574 10.1136/gutjnl-2013-304488
A. Spinelli et al. ECCO guidelines on therapeutics in ulcerative colitis: surgical treatment J. Crohns Colitis 16 179 189 34635910 10.1093/ecco-jcc/jjab177
J.N. Cohan P. Bacchetti M.G. Varma E. Finlayson Impact of patient age on procedure type for ulcerative colitis: a national study Dis. Colon. Rectum 58 769 774 26163956 10.1097/DCR.0000000000000398
S.J. Halpin A.C. Ford Prevalence of symptoms meeting criteria for irritable bowel syndrome in inflammatory bowel disease: systematic review and meta-analysis Am. J. Gastroenterol. 107 1474 1482 22929759 10.1038/ajg.2012.260
J.F. Colombel A. Shin P.R. Gibson AGA clinical practice update on functional gastrointestinal symptoms in patients with inflammatory bowel disease: expert review Clin. Gastroenterol. Hepatol. 17 380 390 30099108 10.1016/j.cgh.2018.08.001
M. Lenicek et al. Bile acid malabsorption in inflammatory bowel disease: assessment by serum markers Inflamm. Bowel Dis. 17 1322 1327 21058331 10.1002/ibd.21502
M. Camilleri et al. Measurement of serum 7α-hydroxy-4-cholesten-3-one (or 7αC4), a surrogate test for bile acid malabsorption in health, ileal disease and irritable bowel syndrome using liquid chromatography-tandem mass spectrometry Neurogastroenterol. Motil. 21 734 e43 1:CAS:528:DC%2BD1MXpt1OltL8%3D 19368662 2705747 10.1111/j.1365-2982.2009.01288.x
N. Merza et al. Evaluation of alternative treatment strategies for bile acid malabsorption in inflammatory bowel disease patients: a network meta-analysis J. Clin. Med Res 16 33 45 1:CAS:528:DC%2BB2cXhs1GrtbrI 38550552 10970039 10.14740/jocmr5007
S.T. Odunsi-Shiyanbade et al. Effects of chenodeoxycholate and a bile acid sequestrant, colesevelam, on intestinal transit and bowel function Clin. Gastroenterol. Hepatol. 8 159 165 1:CAS:528:DC%2BC3cXjs1Grt7Y%3D 19879973 10.1016/j.cgh.2009.10.020
J.G. Hashash J. Elkins J.D. Lewis D.G. Binion AGA clinical practice update on diet and nutritional therapies in patients with inflammatory bowel disease: expert review Gastroenterology 166 521 532 1:CAS:528:DC%2BB2cXit12itr8%3D 38276922 10.1053/j.gastro.2023.11.303
S.C. Bischoff et al. ESPEN guideline on Clinical Nutrition in inflammatory bowel disease Clin. Nutr. 42 352 379 36739756 10.1016/j.clnu.2022.12.004
F.K. Ghishan P.R. Kiela Vitamins and minerals in inflammatory bowel disease Gastroenterol. Clin. North Am. 46 797 808 29173522 6342481 10.1016/j.gtc.2017.08.011
H. Gordon et al. ECCO guidelines on extraintestinal manifestations in inflammatory bowel disease J. Crohns Colitis 18 1 37 37351850 10.1093/ecco-jcc/jjad108
T. Kucharzik et al. ECCO guidelines on the prevention, diagnosis, and management of infections in inflammatory bowel disease J. Crohns Colitis 15 879 913 1:STN:280:DC%2BB3sjos1GnsA%3D%3D 33730753 10.1093/ecco-jcc/jjab052
C. Loras et al. Liver dysfunction related to hepatitis B and C in patients with inflammatory bowel disease treated with immunosuppressive therapy Gut 59 1340 1346 1:STN:280:DC%2BC3cfivVOnug%3D%3D 20577000 10.1136/gut.2010.208413
S.H. Park et al. Clinical courses of chronic hepatitis B virus infection and inflammatory bowel disease in patients with both diseases Inflamm. Bowel Dis. 18 2004 2010 22337144 10.1002/ibd.22905
K. Song D. Wu Shared decision-making in the management of patients with inflammatory bowel disease World J. Gastroenterol. 28 3092 3100 1:CAS:528:DC%2BB38XitVOru7fI 36051346 9331519 10.3748/wjg.v28.i26.3092
J.H. Lofland et al. Shared decision-making for biologic treatment of autoimmune disease: Influence on adherence, persistence, satisfaction, and health care costs Patient Prefer Adherence 11 947 958 28572722 5441672 10.2147/PPA.S133222
R. Atreya M.F. Neurath Biomarkers for personalizing IBD therapy: the quest continues Clin. Gastroenterol. Hepatol. 22 1353 1364 1:CAS:528:DC%2BB2cXltlKlu7c%3D 38320679 10.1016/j.cgh.2024.01.026
B. Verstockt et al. Results of the seventh scientific workshop of ECCO: precision medicine in IBD-disease outcome and response to therapy J. Crohns Colitis 15 1431 1442 33730756 8681673 10.1093/ecco-jcc/jjab050
D. Biasci et al. A blood-based prognostic biomarker in IBD Gut 68 1386 1395 1:CAS:528:DC%2BC1MXitVans7zL 31030191 10.1136/gutjnl-2019-318343
P.S. Dulai et al. Development and validation of a scoring system to predict outcomes of vedolizumab treatment in patients with Crohn’s disease Gastroenterology 155 687 695 29857091 10.1053/j.gastro.2018.05.039
A. Sazonovs et al. HLA-DQA1*05 carriage associated with development of anti-drug antibodies to infliximab and adalimumab in patients with Crohn’s disease Gastroenterology 158 189 199 1:CAS:528:DC%2BB3cXhtVOlsbvJ 31600487 10.1053/j.gastro.2019.09.041
N.R. West et al. Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor–neutralizing therapy in patients with inflammatory bowel disease Nat. Med 23 579 589 1:CAS:528:DC%2BC2sXlsV2hu70%3D 28368383 5420447 10.1038/nm.4307
R. Gaujoux et al. Cell-centred meta-Analysis reveals baseline predictors of anti-TNFα non-response in biopsy and blood of patients with IBD Gut 68 604 614 1:CAS:528:DC%2BC1MXhtlSktb3L 29618496 10.1136/gutjnl-2017-315494
J.C. Martin et al. Single-cell analysis of Crohn’s disease lesions identifies a pathogenic cellular module associated with resistance to anti-TNF therapy Cell 178 1493 1508 1:CAS:528:DC%2BC1MXhslSqur7N 31474370 7060942 10.1016/j.cell.2019.08.008
World Health Organization. Health Promotion Glossary (WHO, 1998).
P. Sudhakar et al. Holistic healthcare in inflammatory bowel disease: time for patient-centric approaches? Gut 72 192 204 1:CAS:528:DC%2BB38XjtFKms7vF 36171081 10.1136/gutjnl-2022-328221
B.M. Calkins A meta-analysis of the role of smoking in inflammatory bowel disease Dig. Dis. Sci. 34 1841 1854 1:STN:280:DyaK3c%2FptFOjtA%3D%3D 2598752 10.1007/BF01536701
J.L. Benjamin et al. Smokers with active Crohn’s disease have a clinically relevant dysbiosis of the gastrointestinal microbiota Inflamm. Bowel Dis. 18 1092 1100 22102318 10.1002/ibd.21864
B.E. Sands et al. Risk of early surgery for Crohn’s disease: implications for early treatment strategies Am. J. Gastroenterol. 98 2712 2718 14687822 10.1111/j.1572-0241.2003.08674.x
J. Cosnes L. Beaugerie F. Carbonnel J.P. Gendre Smoking cessation and the course of Crohn’s disease: an intervention study Gastroenterology 120 1093 1099 1:STN:280:DC%2BD3M7mvFOqtQ%3D%3D 11266373 10.1053/gast.2001.23231
S. Coward et al. Funding a smoking cessation program for Crohn’s disease: An economic evaluation Am. J. Gastroenterol. 110 368 377 25350768 10.1038/ajg.2014.300
A.S. Bancil et al. Food additive emulsifiers and their impact on gut microbiome, permeability, and inflammation: mechanistic insights in inflammatory bowel disease J. Crohns Colitis 15 1068 1079 33336247 10.1093/ecco-jcc/jjaa254
K. Whelan A.S. Bancil J.O. Lindsay B. Chassaing Ultra-processed foods and food additives in gut health and disease Nat. Rev. Gastroenterol. Hepatol. 21 406 427 38388570 10.1038/s41575-024-00893-5
N. Narula et al. Food processing and risk of inflammatory bowel disease: a systematic review and meta-analysis Clin. Gastroenterol. Hepatol. 21 2483 2495.e1 36731590 10.1016/j.cgh.2023.01.012
S.R. Cox et al. Effects of low FODMAP diet on symptoms, fecal microbiome, and markers of inflammation in patients with quiescent inflammatory bowel disease in a randomized trial Gastroenterology 158 176 188 1:CAS:528:DC%2BB3cXhtVOlsbvP 31586453 10.1053/j.gastro.2019.09.024
Z. Peng J. Yi X. Liu A low-FODMAP diet provides benefits for functional gastrointestinal symptoms but not for improving stool consistency and mucosal inflammation in IBD: a systematic review and meta-analysis Nutrients 14 2072 1:CAS:528:DC%2BB38XhsVCru7bM 35631213 9146862 10.3390/nu14102072
K. Jones R. Kimble K. Baker G.A. Tew Effects of structured exercise programmes on physiological and psychological outcomes in adults with inflammatory bowel disease (IBD): a systematic review and meta-analysis PLoS ONE 17 1:CAS:528:DC%2BB38XjtFegsL3F 36454911 9714897 10.1371/journal.pone.0278480 e0278480
M. Raman et al. Physical activity in patients with inflammatory bowel disease: a narrative review Inflamm. Bowel Dis. 28 1100 1111 34605548 10.1093/ibd/izab218
G. Conroy Why is exercise good for you? Scientists are finding answers in our cells Nature 629 26 28 1:CAS:528:DC%2BB2cXpsl2rt7o%3D 38693406 10.1038/d41586-024-01200-7
J.J. Rozich A. Holmer S. Singh Effect of lifestyle factors on outcomes in patients with inflammatory bowel diseases Am. J. Gastroenterol. 115 832 840 32224703 7274876 10.14309/ajg.0000000000000608
N.Z. Borren C.J. van der Woude A.N. Ananthakrishnan Fatigue in IBD: epidemiology, pathophysiology and management Nat. Rev. Gastroenterol. Hepatol. 16 247 259 1:CAS:528:DC%2BC1cXisFWrtLfM 30531816 10.1038/s41575-018-0091-9
A.N. Ananthakrishnan M.D. Long C.F. Martin R.S. Sandler M.D. Kappelman Sleep disturbance and risk of active disease in patients with Crohn’s disease and ulcerative colitis Clin. Gastroenterol. Hepatol. 11 965 971 23376797 3659204 10.1016/j.cgh.2013.01.021
I. Habib A. Mazulis G. Roginsky E.D. Ehrenpreis Nonsteroidal anti-inflammatory drugs and inflammatory bowel disease: pathophysiology and clinical associations Inflamm. Bowel Dis. 20 2493 2502 25230166 10.1097/MIB.0000000000000165
